MOMENTUM, a phase III study in symptomatic, anemic patients with myelofibrosis who were previously treated with a JAK inhibitor, showed that momelotinib significantly improved disease-related symptoms compared to danazol. At the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, Mesa et al presented results from the trial on patient-reported health status and health-related quality of life analyses (Abstract 4351).
